Ryvu Therapeutics SA
RVU · GPW
Public Market Listing
Live quotes, historical charts, and market capitalization for Ryvu Therapeutics SA are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | CDK8 / CDK19Small molecule | Acute Myeloid Leukemia |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (1)
August 2027 (1)
What to watch
Financial reports
Quarterly & interim (3)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q3 | $17M | $39M | $25M | $23M | report ↗ |
Ryvu Therapeutics SA reported revenue of $17.01M, R&D spend of $38.97M, cash and equivalents of $24.52M, and a net loss of $22.98M for Q3 2025.
Figures only: this period's report disclosed no narrative text
View 2 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-H1 | $11M | $25M | $30M | $7.6M | report ↗ |
| 2025-Q1 | $5.3M | $12M | $39M | $6.3M | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $23M | $48M | $17M | — | report ↗ |